Clinical Trial Update: Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating imaging with 68Ga-DOTATATE PET/CT, Octreotide, and F-DOPA PET for ectopic Cushing syndrome due to ACTH, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome
• Ectopic Cushing Syndrome

Drugs mentioned

• 68Ga-DOTATATE (Gallium-68 DOTATATE)
• F-DOPA (fluorodopa)
• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: ACTH, Cushing's Syndrome | Phase 2 | Status: RECRUITING